| Literature DB >> 33244346 |
Kosisochi Chinwendu Amorha1, Kingsley Emeka Idoko1, Mathew Jegbefume Okonta1, Chinwe Victoria Ukwe1.
Abstract
INTRODUCTION: few studies have been conducted to evaluate pharmacists´ knowledge and practice of the asthma guidelines. The Global Initiative for Asthma (GINA) report was developed to reduce practice variability and to improve the quality of asthma care. This study aimed to assess the knowledge and practice of the GINA report among community pharmacists in a Nigerian State.Entities:
Keywords: Asthma; GINA; community pharmacists; knowledge; practice
Mesh:
Year: 2020 PMID: 33244346 PMCID: PMC7680245 DOI: 10.11604/pamj.2020.37.83.18897
Source DB: PubMed Journal: Pan Afr Med J
demographic of the community pharmacists in the survey, n = 89
| Variables | n (%) |
|---|---|
| 20 – 29 | 26 (29.2) |
| 30 – 39 | 28 (31.5) |
| 40 – 49 | 23 (25.8) |
| 50 – 59 | 1 (1.1) |
| >60 | 11 (12.4) |
| Male | 53 (59.6) |
| Female | 36 (40.4) |
| <5 | 22 (24.7) |
| 5 – 10 | 33 (37.1) |
| 11 – 20 | 19 (21.3) |
| >20 | 15 (16.9) |
| <5 | 48 (53.9) |
| 5 – 10 | 20 (22.5) |
| 11 – 20 | 14 (15.7) |
| >20 | 7 (7.9) |
| M.Sc/M.Pharm | 7 (7.9) |
| MPH | 3 (3.4) |
| FPCPharm | 5 (5.6) |
| Ph. D | 0 (0.0) |
| B.Pharm | 74 (83.1) |
knowledge of asthma based on the GINA report, n = 89
| Statements (correct answer) | n (%) |
|---|---|
| The use of more than one canister of short-acting inhaled β2-agonists per month indicates inadequate disease control (true) | 48 (53.9) |
| Inhaled corticosteroids act as direct bronchodilators (false) | 42 (47.2) |
| Salmeterol xinafoate is an example of an inhaled steroid (false) | 42 (48.3) |
| Cough which is worse at night, wheezing and recurrent chest tightness are suggestive of asthma (true) | 78 (87.6) |
| The use of long-acting inhaled β2-agonists can help many asthmatics discontinue steroids (false) | 26 (29.2) |
| Inhaled anticholinergic agents are not the most indicated drugs for long-term control of asthma (true) | 55 (61.8) |
| For asthma patients without symptoms between attacks, short-acting inhaled β2-agonists, as needed, are usually sufficient (true) | 52 (58.4) |
| Patient education in the management of asthma cannot improve inhaler technique (false) | 81 (91.0) |
practice of the GINA report, n = 89
| Scenario (correct answer) | n (%) |
|---|---|
| A 40 y/o male with cough and wheezing at nights; overuses salbutamol inhaler with little relief (prescribe a single ingredient inhaled steroid) | 7 (7.9) |
| 2. A 35 y/o female with poor asthma control; on regular fluticasone 250mcg twice daily and salbutamol inhaler when necessary (Prescribe a long acting beta agonist (LABA) or combination of inhaled steroid/LABA) | 3 (3.4) |
| 3. A 72 y/o female with symptoms upon exertion; on regular budesonide 160mcg/formoterol fumarate 4.5mcg once daily and salbutamol inhaler when necessary (Increase dose of the combination inhaled steroid/LABA to twice daily) | 3 (3.4) |
| A 27 y/o male collecting salbutamol inhaler prescription; has had no symptoms in the last 9 months (no action. He should use the salbutamol inhaler only when necessary or as needed) | 0 (0.0) |
| A 62 y/o female on fluticasone 250mcg/salmeterol 50mcg twice daily and both salbutamol and ipratropium for relief (removal of second reliever) | 1 (1.1) |
| A 65 y/o male has a cold, with symptoms of a lot of trouble breathing and trouble sleeping. He is currently on 160mcg/formoterol fumarate 4.5mcg twice daily; salbutamol inhaler for relief, when necessary; montelukast 10mg once daily in the evening (prescribe a short course of oral steroid) | 1 (1.1) |
| A 43 y/o female has not had to use salbutamol inhaler for a very long time; feels well. She has been on fluticasone 100mcg/salmeterol 50mcg twice daily (remove LABA) | 1 (1.1) |
barriers to adherence to the GINA report, n = 89
| Variables | SD | D | A | SA | Mean (SDv) |
|---|---|---|---|---|---|
| Lack of interviewing place/counselling room | 7 (7.9) | 33 (37.1) | 24 (27.0) | 25 (28.1) | 2.75 (0.96) |
| Lack of peak flow meters | 5 (5.6) | 22 (24.7) | 38 (42.7) | 24 (27.0) | 2.91 (0.86) |
| Lack of required medications | 7 (7.9) | 25 (28.1) | 35 (39.3) | 22 (24.7) | 2.81 (0.90) |
| Lack of asthma action plan | 1 (1.1) | 10 (11.2) | 51 (57.3) | 27 (30.3) | 3.17 (0.66) |
| Lack of asthma records | 0 (0.0) | 13 (14.6) | 47 (52.8) | 29 (32.6) | 3.18 (0.67) |
| Lack of multi-disciplinary approach | 0 (0.0) | 17 (19.1) | 48 (53.9) | 24 (27.0) | 3.08 (0.68) |
| Defective referral system | 1 (1.1) | 11 (12.4) | 42 (49.2) | 35 (39.3) | 3.25 (0.71) |
| Lack of training | 5 (5.6) | 18 (20.2) | 34 (38.2) | 32 (36.0) | 3.04 (0.89) |
| Lack of knowledge | 2 (2.2) | 24 (27.0) | 38 (42.7) | 25 (28.1) | 2.97 (0.80) |
| Time constraints | 0 (0.0) | 24 (27.0) | 35 (39.3) | 30 (33.7) | 3.07 (0.78) |
| Not complying with management | 0 (0.0) | 2 (2.2) | 31 (34.8) | 56 (62.9) | 3.61 (0.54) |
| Not adhering to follow-up schedules | 0 (0.0) | 0 (0.0) | 36 (40.4) | 53 (59.6) | 3.60 (0.49) |
| Hiding the disease | 1 (1.1) | 11 (12.4) | 33 (37.1) | 44 (49.4) | 3.35 (0.74) |
SD = strongly disagree (coded as 1); D = disagree (coded as 2); A = agree (coded as 3); SA = strongly agree (coded as 4); SDv = standard deviation
association between the demographic variables and community pharmacists’ knowledge and practice of the GINA report, n = 89
| Variables | Poor knowledge | Good knowledge | Total | χ2 | P-value | Poor practice | Good practice | Total | χ2 | P-value |
|---|---|---|---|---|---|---|---|---|---|---|
| 20 – 29 | 16 (27.6) | 10 (32.3) | 26 (29.2) | 22 (27.8) | 4 (40.0) | 26 (29.2) | ||||
| 30 – 39 | 17 (29.3) | 11 (35.5) | 28 (31.5) | 25 (31.6) | 3 (30.0) | 28 (31.5) | ||||
| 40 – 49 | 17 (29.3) | 6 (19.4) | 23 (25.8) | 20 (25.3) | 3 (30.0) | 23 (25.8) | ||||
| 50 – 59 | 1 (1.7) | 0 (0.0) | 1 (1.1) | 1 (1. 3) | 0 (0.0) | 1 (1.1) | ||||
| >60 | 7 (12.1) | 4 (12.9) | 11 (12.4) | 11 (13.9) | 0 (0.0) | 11 (12.4) | ||||
| Male | 32 (55.2) | 21 (67.1) | 53 (59.6) | 47 (59.5) | 6 (60.0) | 53 (59.6) | ||||
| Female | 26 (44.8) | 10 (32.3) | 36 (40.4) | 32 (40.5) | 4 (40.0) | 36 (40.4) | ||||
| <5 | 12 (20.7) | 10 (32.3) | 22 (24.7) | 19 (24.1) | 3 (30.0) | 22 ( 24.7) | ||||
| 5 – 10 | 24 (41.4) | 9 (29.0) | 33 (37.1) | 30 (38.0) | 3 (30.0) | 33 (37.1) | ||||
| 11 – 20 | 11 (19.0) | 8 (25.8) | 19 (21.3) | 15 (19.0) | 4 (40.0) | 19 ( 21.3) | ||||
| >20 | 11 (19.0) | 4 (12.9) | 15 (16.9) | 15 (19.0) | 0 (0.0) | 15 (16.9) | ||||
| <5 | 31 (53.4) | 17 (54.8) | 48 (53.9) | 43 (54.1) | 5 (50.0) | 48 (53.9) | ||||
| 5 – 10 | 15 (25.9) | 5 (16.1) | 20 (22.5) | 17 (21.5) | 3 (30.0) | 20 (22.5) | ||||
| 11 – 20 | 6 (10.3) | 8 (25.8) | 14 (15.7) | 12 (15.9) | 2 (20.0) | 14 (15.7) | ||||
| >20 | 6 (10.3) | 1 (3.2) | 7 (7.9) | 7 (8.9) | 0 (0.0) | 7 (7.9) |
P <0.05 shows statistical significance